Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05954039
Other study ID # IT0003492/22
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2022
Est. completion date December 23, 2022

Study information

Verified date July 2023
Source Seppic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is aimed to assess the efficacy of a dietary supplement composed of a Wheat Polar Lipid Complex (WPLC) in reducing hair loss and improving hair aspect.


Description:

A double blind, parallel groups, placebo-controlled study is carried out on 60 healthy female subjects aged between 18 and 65 years old with all hair type showing diffuse and temporary hair shedding with a proportion of hair in telogen phase >15%. The study foresees 84 days of products intake. Evaluations of the parameters under study are performed at baseline, after 56 and 84 days of products consumption.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date December 23, 2022
Est. primary completion date December 23, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion criteria : - Healthy female subjects, - Caucasian ethnicity, - Age between 18 and 65 years old, - All hair type included, - Women showing a proportion of hair in telogen phase > 15%, - Subjects complaining brittle and thin hair, - Subjects who stopped any anti hair loss treatment at least 3 months prior the study, - Subjects agreeing not to take any treatment (oral or topic) able to interfere with the hair growth, diameter or fall during the whole study duration, - Subjects who have not been involved in any other similar in the last 3 months, - Subjects registered with health social security or health social insurance, - Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial, - Subjects able to understand the language used in the investigation center and the information given, - Subjects able to comply with the protocol and follow protocol's constraints and specific requirements, - Willingness to use the same products for hair care during all the study period, - Willingness not to cut hair for all the study length, - Subjects having signed their written Informed Consent form (ICF) for their participation in the study and a photograph authorization. Exclusion Criteria: - Subject does not meet the inclusion criteria, - Subject is taking part or planning to participate to another clinical study in the same or in another investigation centre, - Subject is deprived of freedom by administrative or legal decision or under guardianship, - Subject is admitted in a sanitary or social facilities, - Subject is planning an hospitalization during the study, - Subject has participated in another clinical study with anti-hair loss product or treatment within the last 24 weeks before the inclusion visit, - Subject is breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential), - Subject has started or changed oestrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study, - Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements, - Subject is in course of a long-treatment or intending to have one considered by the Investigator liable to interfere with the study data or incompatible with the study requirements, - Subject having a skin/scalp condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements, - Subject having personal history of cosmetic, drug, domestic products or food supplements allergy, - Subject having food disorders, - Subject who has any other hair disorder or hair disease (female pattern hair loss, any type of alopecia...), - Subject having excessive and/or fluctuating hair shedding for more than 6 months, - History or clinical signs of hyperandrogenemia (menstrual cycle >35 days and hirsutism and acne), - Systemic treatment affecting the hair growth taken for more than 4 consecutive weeks during the last 24 weeks before inclusion visit: retinoids, anti-mitotic, cytotoxic drugs other than antineoplastic, anti-androgens (spironolactone, flutamide), androgens, anti-epileptic agents, interferon alpha, - Systemic or local androgenetic alopecia treatment or product, taken or applied (Minoxidil, Aminexil, Finasteride, Dutasteride, cosmetic solution or capsules with vitamin B, zinc, caffeine...) for more than 4 consecutive weeks during the last 24 weeks before the inclusion visit, - Any other topical treatment applied on the scalp (non-steroidal anti-inflammatory, ketoconazole...) within the last 2 weeks before the inclusion visit, - No hair wash in the 48 hours before each visit, - Any following hair care within the last 2 weeks before each visit: dandruff shampoo, antifungal shampoo, dyeing, bleaching, perm, - Any hair care product applied on the scalp between the last shampoo and the inclusion visit (e.g. gel, hairspray, wax, foam...), - Radiotherapy, chemotherapy at any time, - Scalp surgery (hair transplants, laser) at any time

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Wheat Polar Lipid Complex
The study foresees the intake of 2 capsules per day during 84 days
Placebo
The study foresees the intake of 2 capsules per day during 84 days

Locations

Country Name City State
Italy Complife Italia srl Milano

Sponsors (1)

Lead Sponsor Collaborator
Seppic

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Telogen hair proportion Phototrichogram Baseline
Primary Telogen hair proportion Phototrichogram 56 days
Primary Telogen hair proportion Phototrichogram 84 days
Secondary Anagen hair proportion Phototrichogram Baseline
Secondary Anagen hair proportion Phototrichogram 56 days
Secondary Anagen hair proportion Phototrichogram 84 days
Secondary Hair growth Hair length after shaving 84 days
Secondary Hair elasticity Hair elongation using dynamometer Baseline
Secondary Hair elasticity Hair elongation using dynamometer 84 days
Secondary Scalp sebum content Sebumeter Baseline
Secondary Scalp sebum content Sebumeter 56 days
Secondary Scalp sebum content Sebumeter 84 days
Secondary Hair diameter Optical microscopy Baseline
Secondary Hair diameter Optical microscopy 84 days
Secondary Hair loss Pull test Baseline
Secondary Hair loss Pull test 56 days
Secondary Hair loss Pull test 84 days
Secondary Hair density Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight density and 10 = very important density) Baseline
Secondary Hair density Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight density and 10 = very important density) 56 days
Secondary Hair density Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight density and 10 = very important density) 84 days
Secondary Hair volume Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight volume and 10 = very important volume) Baseline
Secondary Hair volume Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight volume and 10 = very important volume) 56 days
Secondary Hair volume Clinical scoring (Visual analog scale from 0 to 10, where: 0 = very slight volume and 10 = very important volume) 84 days
Secondary Self-assessment of product efficacy Questionnaire (20 questions with 4 possible answers : completely agree / agree / disagree / completely disagree) 84 days
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1
Not yet recruiting NCT06236009 - A First-In-Human Study of TAK-004 in Healthy Adults Phase 1